Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lenalidomide and Blinatumomab in Relapsed/Refractory NHL
NCT02568553Phase 1Completed
- Sponsor
- National Cancer Institute
- Start
- Nov 2016
- Primary completion
- Nov 2025
- Modality
- Antibody Conjugates, scFv Fragments, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of blinatumomab and lenalidomide in non-Hodgkin lymphoma (NHL), sponsored by National Cancer Institute. Primary endpoints: Maximum Tolerated Dose of Lenalidomide and Incidence of toxicity up to 24 months. Started Nov 2016; status: completed.
02
Drugs
blinatumomablenalidomide
03
Conditions
non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NCT02568553.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02568553.